With support from NFL owner Jeffrey Lurie, Icelandic biotech closes Series A for oral Alzheimer's drug

Max Gelman

Senior Editor

A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral treatments for Alzheimer’s disease and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With support from NFL owner Jeffrey Lurie, Icelandic biotech closes Series A for oral Alzheimer's drug

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

US withdrawal from WHO could jeopardize information sharing

China's biotech boom is threatening US drugmakers' dominance

Sanofi says no supply interruptions after landing FDA warning letter for US site

Renewed mifepristone fight will be early test of Trump’s abortion stance in his second term

J&J's Spravato wins expanded label for depression as singular treatment

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

With sup­port from NFL own­er Jef­frey Lurie, Ice­landic biotech clos­es Se­ries A for oral Alzheimer's drug

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With support from NFL owner Jeffrey Lurie, Icelandic biotech closes Series A for oral Alzheimer's drug